Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis [PDF]
, 2016 Search strategy.
Lei Zhao, Quan Fang, Zhuang Tian
core +2 more sources
Tafamidis in Transthyretin Amyloid Cardiomyopathy [PDF]
Circulation: Heart Failure, 2015 Background— Transthyretin (TTR) amyloidosis is a progressive systemic disorder caused by misfolded TTR monomers that cumulatively deposit in the heart and systemically as amyloid. Methods and Results— This phase 2 open-label trial evaluated the stabilization of TTR tetramers using ...
Mathew S, Maurer +8 more
openaire +2 more sources
Urinary Biomarkers for Kidney Disease in ATTR Amyloidosis [PDF]
, 2014 Aim: The detection and prognosis of nephropathy in transthyretin amyloidosis depends on albuminuria and renal function. Knowing that urinary levels of alpha-1 microglobulin and beta-2 microglobulin reflect tubular dysfunction while urinary alpha-2 ...
Beirão, I. +5 more
core +1 more source
Familial amyloidosis with polyneuropathy type 1 caused by transthyretin mutation Val50Met (Val30Met): 4 cases in a non-endemic area [PDF]
, 2018 Introduction: Transthyretin-related familial amyloid polyneuropathy (TTR-FAP) typically arises as an autonomic neuropathy primarily affecting small fibres and it occurs in adult patients in their second or third decades of life. It progresses rapidly and
Andrés, N. +2 more
core +3 more sources
A Narrative Review of the Role of Transthyretin in Health and Disease
Neurology and Therapy, 2020 Transthyretin (TTR) is a tetrameric transport protein highly conserved through vertebrate evolution and synthesized in the liver, choroid plexus, and retinal pigment epithelium. TTR transports the thyroid hormone thyroxine and the retinol-binding protein
Marcia Almeida Liz +5 more
doaj +1 more source
Senile Systemic Amyloidosis: An Underdiagnosed Disease [PDF]
, 2017 Senile systemic amyloidosis is caused by a non-mutated form of transthyretin with the heart being the major organ involved. This infiltrative cardiomyopathy usually presents as slowly progressive heart failure.
Domingos, Raquel +4 more
core +3 more sources
ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya +9 more
wiley +1 more source
Healthcare resource use of patients with transthyretin amyloid cardiomyopathy
ESC Heart Failure, 2022 Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is the cardiac manifestation of transthyretin amyloidosis (ATTR). The aim of this study was to estimate healthcare resource use for ATTR‐CM patients compared with heart failure (HF) patients, in Denmark,
Rosa Lauppe +10 more
doaj +1 more source
Misdiagnosis of hereditary amyloidosis as AL (Primary) amyloidosis [PDF]
, 2002 Background: Hereditary, autosomal dominant amyloidosis, caused by mutations in the genes encoding transthyretin, fibrinogen A -chain, lysozyme, or apolipoprotein A-I, is thought to be extremely rare and is not routinely included in the differential ...
Booth, D.R. +7 more
core
Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition [PDF]
, 2018 Each of the 30 human amyloid diseases is associated with the aggregation of a particular precursor protein into amyloid fibrils. In transthyretin amyloidosis (ATTR), mutant or wild-type forms of the serum carrier protein transthyretin (TTR), synthesized ...
Benson, Merrill D. +6 more
core +1 more source